ICLUSIG® (ponatinib) is a prescription medicine used to treat adults who have:
- a specific type of abnormal gene (T315I-positive) chronic phase, accelerated phase, or blast phase myeloid leukemia (CML), or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
- chronic phase, accelerated phase, or blast phase CML or Ph+ ALL who cannot receive any other tyrosine kinase inhibitor (TKI) medicines.
It is not known if ICLUSIG is safe and effective in children less than 18 years of age.
ICLUSIG was approved by the Food and Drug Administration (FDA) based on how patients responded during treatment with ICLUSIG. Studies have not shown that ICLUSIG improved the symptoms of these patients or helped them live longer.